A 'second life' agenda: Psychiatric research issues raised by protease inhibitor treatments for people with the human immunodeficiency virus or the acquired immunodeficiency syndrome

Archives of General Psychiatry

Volumn 54, Issue 11, 1997, Pages 1049-1053

  Rabkin, Judith G ^a   Ferrando, Stephen ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; ILLICIT DRUG; LORAZEPAM; METHADONE; NEFAZODONE; NEUROLEPTIC AGENT; PROTEINASE INHIBITOR; PSYCHOTROPIC AGENT; VALPROIC ACID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISTRESS SYNDROME; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIFE; MEDICAL RESEARCH; NEUROPSYCHIATRY; REVIEW; TREATMENT FAILURE;

EID: 0030659633     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830230091013     Document Type: Review

References (43)

1. Henrad DR, Phillips JF, Muenz LR, Blattner WA, Wiesner D, Eyster ME, Goedert J. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274:554-558.
2. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med. 1996;334:426-431.
3. Ho DD. Viral counts count in HIV infection. Science. 1996;272:1123-1125.
4. Saag MS, Holodniy M, Kuritzkes D, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA. HIV viral load markers in clinical practice. Nat Med. 1996;82:625-629.
5. Mulder J, McKinney N, Christopherson J, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol. 1994;32:292-300.
6. Dewar RL, Highbarger H, Sarmiento MD, Todd J, Vasudevachari MB, Davey R, Kovacs JA, Salzman NP, Lane HC, Urdea MS. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 in human plasma. J Infect Dis. 1994;170:1172-1179.
7. Steele FR. Optimism invades HIV conference. Nat Med. 1996;2:257-258.
8. Carpenter C, Fischl M, Hammer S, Hirsch M, Jacobsen D, Katzenstein D, Montaner JS, Richman D, Saag S, Schooley R, Thompson M, Vella S, Yeni P, Volberding P, for the International AIDS Society. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
9. Sullivan A. When plagues end: notes on the twilight of an epidemic. New York Times Magazine. November 10, 1996:23ff.
10. Altman L. US reporting sharp decrease in AIDS deaths. The New York Times. February 28, 1997; A1, A10.
11. Altman L. Discussing possible AIDS cure raises hope, anger and question: what exactly is meant by cure? The New York Times. July 16, 1996:C3.
12. Anders G. Able to work again, AIDS patients worry about disability pay. Wall Street Journal. November 18, 1996:1.
13. Roberts NA. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS. 1995; 9(suppl 2):S27-S32.
14. Shater RW, Edlin BR. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis. 1996; 22:683-704.
15. Curtis R, Friedman SR, Neaigus A, Jose B, Goldstein M, DesJarlais DC. Implications of directly observed therapy in tuberculosis control measures among IDUs. Public Health Rep. 1994;109:327-329.
16. Meichenbaum D, Turk D. Facilitating Treatment Adherence. New York, NY: Plenum Publishing Corp; 1987.
17. Sumartojo E. When tuberculosis treatment fails: a social behavioral account of patient adherence. Am Rev Respir Dis. 1993;147:1311-1320.
18. Wall TL, Sorensen JL, Batki SL, Delucchi KL, London JA, Chesney MA. Adherence to zidovudine (AZT) among HIV-infected methadone patients: a pilot study of supervised therapy and dispensing compared to usual care. Drug Alcohol Depend. 1995;37:261-269.
19. Green J. Flirting with suicide. New York Times Magazine. September 15, 1996:38ff.
20. Krieger JN, Coombs R, Collier A, Ross S, Chaloupka K, Cummings D, Murphy VL, Corey L. Recovery of human immunodeficiency virus type 1 from semen: minimal impact of stage of infection and current antiviral chemotherapy. J Infect Dis. 1991;163:386-388.
21. Gilden D. When HAART is not enough. Gay Mens Health Crisis Treatment Issues. 1996;10:1-3.
22. Rando T. Treatment of Complicated Mourning. Champaign, III: Research Press; 1993.
23. Horowitz M, Kaltreider N. Brief therapy of the stress response syndrome. Psychiatr Clin North A. 1979;2:365-377.
24. Goodkin K, Blaney N, Feaster D, Burkhalter J, Leeds B, Tuttle R, Fletcher MA. A bereavement support group decreases distress in HIV-infected gay men. Presented at the 10th International Conference on AIDS; August 8, 1994; Yokohama, Japan.
25. Grant I, Atkinson J, Hesselink J, Kennedy CJ, Richman DD, Spector SA, McCutchan JA. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Ann Intern Med, 1987;103:828-836.
26. Janssen RS, and the Working Group of the American Academy of Neurology AIDS Task Force. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41:778-785.
27. McArthur J, Harrison MJ. HIV-associated dementia. Current Neurology. St Louis, Mo: Mosby-Year Book Inc; 1994;14:chap 10.
28. Maj M, Janssen R, Starace F, Zaudig M, Satz P, Sughondhabirom B, Luabeya M, Riedel R, Ndetei D, Calil HM, Bing EG, St Louis M, Sartorius N. WHO Neuropsychiatric AIDS study, cross-sectional phase I. Arch Gen Psychiatry. 1994;51:39-49.
29. Bacellar H, Munoz A, Miller EN, Cohen BA, Besley D, Selnes OA, Becker JT, McArthur J. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992. Neurology. 1994;44:1892-1900.
30. Heaton RK, Grant I, Butters N, White DA, Kirson D, Atkinson JH, McCutchan JA, Taylor MJ, Kelly MD, Elite RJ, Wolfson T, Velin R, Marcotte TD, Hesselink JR, Jernigan TL, Chandler J, Wallace M, Abramson I, and the HNRC group. The HNRC 500: neuropsychology of HIV infection at different disease stages. J Int Neuropsychol Soc. 1995;1:231-251.
31. Heaton RK, Velin RA, McCutchan JA, Gulevich SJ, Atkinson JH, Wallace MR, Godfrey HPD, Kirson DA, Grant I, and the HNRC group. Neuropsychological impairment in human immunodeficiency virus-infection: implications for employment. Psychosom Med. 1994;56:8-17.
32. Power C, Kong P, Crawford TO, Wesselingh S, Glass JD, McArthur JC, Trapp BD. Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations in the blood-brain barrier. Ann Neurol. 1993;34:339-350.
33. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA. 1997;277:145-153.
34. McCutchan JA, Ellis R, Hsia R. Relationship of cerebrospinal fluid HIV-1 RNA levels (CSF RNA) to plasma RNA, CSF pleocytosis, stage of HIV infection and cognitive functioning. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections; January 24, 1997; Washington, DC.
35. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry. 1996;153:311-320.
36. Stein MD, Piette J, Mor V, Wachtel TJ, Fleishman J, Mayer KH, Carpenter CC. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991;6:35-40.
37. Ferrando SJ, Wall TW, Batki SL, Sorensen JL. Psychiatric morbidity, illicit drug use and adherence to zidovudine (AZT) among injection drug users with HIV disease. Am J Drug Alcohol Abuse. 1996; 22:475-487.
38. Reichman LB. Compliance with zidovudine therapy. Ann Intern Med. 1990;113:332-333.
39. Samet JH, Libman H, Steger KA, Dhawan RK, Chen J, Shevitz AH, Dewees-Dunk R, Levenson S, Kufe D, Craven DE. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type 1: a cross-sectional study in a municipal hospital clinic. Am J Med. 1992;92: 495-502.
40. Adams SG, Howe TT. Predicting medication compliance in a psychotic population. J Nerv Ment Dis. 1993;181:558-560.
41. Banqsberg D, Tulsky JP, Hecht FM, Moss AR. Protease inhibitors in the homeless. JAMA. 1997; 278:63-65.
42. Volberding PA, Lagakos SW, Grimes JM, Stein DS, Balfour HH Jr, Reichman RC, Bartlett JA, Hirsch M, Phair JP, Mitsuyasu RT, Fischl M, Soeiro R. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437-442.
43. Concorde Coordinating Committee. Concorde: MRC/ANR randomized double-blind controlled trial of immediate and deferred zidovudine in symptomfree HIV infection. Lancet. 1994;343:871-881.